China Unveils 5-Year Bioinnovation Plan

China has issued a five-year plan aimed at boosting innovation in the pharmaceutical and biotech industries, with a focus on enhancing China's global competitiveness and international influence in the pharmaceutical sector between 2026 and 2030. The plan includes key goals such as increasing the proportion of innovative drugs developed in China to make up at least 25% of the global total, with the innovative drug sector growing at an annual rate of no less than 20%. It also projects that the revenues of pharmaceutical companies exceeding 20 million yuan will reach 3.5 trillion yuan by 2030, and that the number of companies with revenues over 10 billion yuan will rise to 50. Additionally, the plan anticipates five Chinese medicines achieving annual sales exceeding one billion US dollars. This strategy comes amidst a rapid transformation in China's industry, shifting from reliance on components to exporting innovative drugs. The country has seen a notable increase in approvals for innovative medicines reaching the global market, with external licensing deals for Chinese innovative drugs rising by 36% so far this year.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل